Short Interest in Trinity Biotech plc (NASDAQ:TRIB) Grows By 70.4%

Trinity Biotech plc (NASDAQ:TRIB) was the recipient of a large growth in short interest during the month of July. As of July 15th, there was short interest totalling 18,400 shares, a growth of 70.4% from the June 30th total of 10,800 shares. Currently, 0.3% of the company’s shares are short sold. Based on an average daily volume of 52,400 shares, the short-interest ratio is currently 0.4 days.

Trinity Biotech Trading Down 4.3 %

Trinity Biotech stock traded down $0.13 during midday trading on Friday, reaching $2.86. 12,640 shares of the stock traded hands, compared to its average volume of 55,254. The firm has a market cap of $21.80 million, a PE ratio of -1.03 and a beta of 1.31. The company has a 50-day simple moving average of $2.36 and a two-hundred day simple moving average of $2.22. Trinity Biotech has a 12-month low of $1.49 and a 12-month high of $5.10.

Trinity Biotech (NASDAQ:TRIB) last issued its quarterly earnings results on Thursday, May 23rd. The company reported ($0.37) earnings per share (EPS) for the quarter. The firm had revenue of $14.70 million for the quarter. Equities research analysts anticipate that Trinity Biotech will post -2.17 earnings per share for the current year.

Analyst Ratings Changes

Separately, StockNews.com initiated coverage on Trinity Biotech in a research note on Sunday, July 21st. They set a “buy” rating on the stock.

About Trinity Biotech

Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.